Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE PHOSPHATE vs Artemether-Lumefantrine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Radical cure of relapsing malaria caused by Plasmodium vivax or P. ovale,Prevention of relapse in malaria due to P. vivax or P. ovale,Off-label: Terminal prophylaxis of malaria (after leaving endemic area) to prevent relapse,Combination therapy for treatment of uncomplicated malaria (with clindamycin or other agents)
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Primaquine is extensively metabolized in the liver, primarily via CYP2C8 and CYP2D6. Major metabolites include carboxyprimaquine and other oxidative products.
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
Approximately 70% bound to plasma proteins (primarily albumin).
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
2.5-3.5 L/kg; extensive distribution into tissues including liver, lungs, and erythrocytes.
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
Oral: approximately 75-80% (first-pass metabolism reduces systemic availability; food decreases rate but not extent).
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
No specific guidelines; use with caution in renal impairment. For severe renal impairment (Cr Cl <30 m L/min), consider alternative therapy due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor for adverse effects; dose adjustment not well defined, but consider reducing dose to 15 mg (base) daily and monitoring G6PD status.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
Children: For radical cure of P. vivax or P. ovale: 0.5 mg/kg (base) orally once daily for 14 days (maximum 30 mg). For prophylaxis: 0.5 mg/kg (base) orally once daily (maximum 30 mg) starting 1 day before travel, daily during travel, and 7 days after leaving endemic area. Must test for G6PD deficiency before use.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
No specific dose adjustments; use with caution due to age-related decline in hepatic and renal function. Monitor for hemolytic anemia and gastrointestinal effects. Consider lower starting dose (15 mg base daily) and adjust based on tolerability.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
Primaquine phosphate can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency must be ruled out before starting treatment. Severe hemolysis may occur and can lead to death.
None
Hemolytic anemia in G6PD-deficient patients: Screen for G6PD deficiency prior to use and avoid in such patients unless benefit outweighs risk,Methemoglobinemia: Can occur, especially in patients with NADH-methemoglobin reductase deficiency or other predisposing conditions,Hematologic toxicity: Monitor blood counts; caution in patients with anemia or other blood disorders,Hepatic impairment: Use with caution; may need dose adjustment,Psychiatric effects: Rarely associated with anxiety, confusion, or psychosis
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
G6PD deficiency (absolute contraindication due to risk of hemolytic anemia),Known hypersensitivity to primaquine or other 8-aminoquinolines,Concurrent use with other hemolytic agents or drugs causing methemoglobinemia,Lupus erythematosus (relative contraindication; may exacerbate),Rheumatoid arthritis (relative contraindication; may exacerbate)
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
Grapefruit juice may increase plasma concentrations of primaquine, raising risk of toxicity. Take with food to reduce gastrointestinal irritation. No other significant food interactions known.
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk of hemolytic anemia in G6PD-deficient fetuses; use only if clearly needed.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
Excreted into breast milk in small amounts. M/P ratio not established. Use caution; avoid in G6PD-deficient infants. Consider risk of hemolytic anemia.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may affect efficacy; however, standard dosing is typically used with careful monitoring.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
Primaquine is the only 8-aminoquinoline used for radical cure of Plasmodium vivax and P. ovale hypnozoites. Screen for G6PD deficiency before initiation to prevent hemolytic anemia. Administer with food to reduce gastrointestinal upset. Watch for methemoglobinemia; discontinue if cyanosis or oxygen saturation drops. Avoid in pregnancy and lactation unless benefit outweighs risk.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
Take with food or milk to prevent stomach upset.,Complete the full course even if you feel better.,Report dark urine, yellowing of skin/eyes, or unusual tiredness immediately.,Avoid grapefruit juice as it may increase side effects.,Do not use during pregnancy or breastfeeding without consulting your doctor.,Keep out of reach of children and store at room temperature.
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE PHOSPHATE vs Artemether-Lumefantrine, answered by our medical review team.
PRIMAQUINE PHOSPHATE is a Antimalarial that works by Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.. Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE PHOSPHATE and Artemether-Lumefantrine depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE PHOSPHATE is: Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.. The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE PHOSPHATE and Artemether-Lumefantrine in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE PHOSPHATE is classified as Category D/X. FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk . Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.